Rhythm Pharmaceuticals wins Japan approval for IMCIVREE in acquired hypothalamic obesity
Rhythm Pharmaceuticals says Japan’s MHLW approved IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity in Japan.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.